Why is this such a big deal? The implications of these numbers go beyond the myocardial infarction indication. The best way to look at his trial is as a sort of proof of concept study. If the company can prove that its technology has a regenerative impact on heart muscle tissue cells, there’s no real reason why it won’t have a similar impact on cells in other regions of the body.
Management just recently reported the initiation of two further preclinical studies, one in NASH and another in critical limb ischemia, and we see this as positive for the treatment’s chances of good MI data.
Why?
Well, it’s speculative, but why would a company kick off an expanded program if the proof of concept looked like it was failing? Chances are that management likes what it is seeing in the MI study and that it’s getting a jump on some expanded indications ahead of putting out the numbers.
We don’t have a target release date for the just initiated studies, but we expect them to take no longer than six months, meaning we should get an indication as to success or failure before the end of the year. Just as with the pending MI data, then, these two studies represent near-term catalysts for the company.
News 
Market Data 
Discover 
AI
